Drug discovery dilemma and Cura Quartet collaboration

Many parties contribute to discovery of new drugs – academic researchers, industry scientists, government agencies, and disease foundation helping to corral the resources necessary to sustain research efforts – but it has never been more apparent until now that these parties must work together to accomplish the shared goal of improving health. At a recent conference at the Georgetown University Medical Center, a group of prominent scientists from the academic, industry, government and disease advocacy communities came together to discuss new paths forward for stronger inter-institutional collaboration to establish a framework for translating new discoveries into drugs, improving proof of concept (PoC) studies, and reducing attrition at the clinical stage of drug development.